

Adult Drug-Resistant TB Medicines Dashboard

This Dashboard has been developed by **Stop TB Partnership/Global Drug Facility** in collaboration with **USAID**, the **World Health Organization** and **The Global Fund to fight AIDS, TB & Malaria**.
Stop TB Partnership/Global Drug Facility licensed the TB Medicines Dashboard under a [Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License](https://creativecommons.org/licenses/by-nc-sa/4.0/).

Medicines	WHO Guidelines (DR-TB '20)	WHO Guidelines (DR-TB '22)	EML submitted	EML (2021)	WHO PQ EOI (2021)	WHO PQ Dossier Under Review	WHO PQ listed	Global Fund List of Pharmaceutical Products	Global Fund ERP EOI (Feb 2023)	Global Fund ERP recommended	GDF Catalog	Status
Amikacin 100mg vial	Yes	Yes	Yes	Yes	No	Ineligible for inclusion	Ineligible for inclusion	No	No	Ineligible for inclusion	Ineligible for inclusion	
Amikacin 500mg/2mL vial	Yes	Yes	Yes	Yes	Yes	N/A	Yes	Yes	Ineligible for inclusion	Ineligible for inclusion	Yes	
Amoxicillin/clavulanate 500mg/125mg tablet	Yes	Yes	Yes	Yes	No	Ineligible for inclusion	Ineligible for inclusion	Yes	Ineligible for inclusion	Ineligible for inclusion	Yes	
Bedaquiline 100mg tablet	Yes	Yes	Yes	Yes	Yes	Yes	No	Yes	Yes	Yes	Yes	
Clofazimine 100mg tablet/capsule	Yes	Yes	Yes	Yes	Yes	N/A	Yes	Yes	Yes	No	Yes	
Clofazimine 50mg tablet/capsule	Yes	Yes	Yes	Yes	Yes	N/A	Yes	Yes	Yes	No	Yes	
Cycloserine 250mg capsule	Yes	Yes	Yes	Yes	Yes	N/A	Yes	Yes	Ineligible for inclusion	Ineligible for inclusion	Yes	

DR-TB: Drug-Resistant TB

EML: Essential Medicines List

EOI: Expression of Interest

ERP: Expert Review Panel

SRA: Stringent Regulatory Authority

WHO PQ: World Health Organization Prequalification of Medicines Programme

Version: February 2023

Adult Drug-Resistant TB Medicines Dashboard

This Dashboard has been developed by **Stop TB Partnership/Global Drug Facility** in collaboration with **USAID**, the **World Health Organization** and **The Global Fund to fight AIDS, TB & Malaria**.
Stop TB Partnership/Global Drug Facility licensed the TB Medicines Dashboard under a [Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License](https://creativecommons.org/licenses/by-nc-sa/4.0/).

Medicines	WHO Guidelines (DR-TB '20)	WHO Guidelines (DR-TB '22)	EML submitted	EML (2021)	WHO PQ EOI (2021)	WHO PQ Dossier Under Review	WHO PQ listed	Global Fund List of Pharmaceutical Products	Global Fund ERP EOI (Feb 2023)	Global Fund ERP recommended	GDF Catalog	Status
Delamanid 50mg tablet	Yes	Yes	Yes	Yes	Yes	N/A	Yes	Yes	Ineligible for inclusion	Ineligible for inclusion	Yes	Yes
Ethambutol 400mg tablet/capsule	Yes	Yes	Yes	Yes	Yes	N/A	Yes	Yes	Ineligible for inclusion	Ineligible for inclusion	Yes	Yes
Ethionamide 250mg tablet/capsule	Yes	Yes	Yes	Yes	Yes	N/A	Yes	Yes	Ineligible for inclusion	Ineligible for inclusion	Yes	Yes
Gatifloxacin 200mg tablet	No	No	Yes	N/A	Yes	No	No	No	No	Ineligible for inclusion	Ineligible for inclusion	No
Gatifloxacin 400mg tablet	No	No	Yes	N/A	Yes	No	No	No	No	Ineligible for inclusion	Ineligible for inclusion	No
Imipenem/cilastatin 250/250mg vial	Yes	Yes	Yes	Yes	No	Ineligible for inclusion	Ineligible for inclusion	Yes	No	Ineligible for inclusion	No	No
Imipenem/cilastatin 500/500mg vial	Yes	Yes	Yes	Yes	Yes	No	No	Yes	Ineligible for inclusion	Ineligible for inclusion	Yes	Yes

DR-TB: Drug-Resistant TB

EML: Essential Medicines List

EOI: Expression of Interest

ERP: Expert Review Panel

SRA: Stringent Regulatory Authority

WHO PQ: World Health Organization Prequalification of Medicines Programme

Version: February 2023

Adult Drug-Resistant TB Medicines Dashboard

This Dashboard has been developed by **Stop TB Partnership/Global Drug Facility** in collaboration with **USAID**, the **World Health Organization** and **The Global Fund to fight AIDS, TB & Malaria**.
Stop TB Partnership/Global Drug Facility licensed the TB Medicines Dashboard under a [Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License](https://creativecommons.org/licenses/by-nc-sa/4.0/).

Medicines	WHO Guidelines (DR-TB '20)	WHO Guidelines (DR-TB '22)	EML submitted	EML (2021)	WHO PQ EOI (2021)	WHO PQ Dossier Under Review	WHO PQ listed	Global Fund List of Pharmaceutical Products	Global Fund ERP EOI (Feb 2023)	Global Fund ERP recommended	GDF Catalog	Status
Imipenem/cilastatin/clavulanate 500/500/125 mg vial	Yes	Yes	No	No	Yes	No	No	No	No	Ineligible for inclusion	Ineligible for inclusion	Ineligible for inclusion
Isoniazid 300mg tablet/capsule	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Ineligible for inclusion	Ineligible for inclusion	Yes	Ineligible for inclusion
Levofloxacin 250mg tablet/capsule	Yes	Yes	Yes	Yes	Yes	N/A	Yes	Yes	Ineligible for inclusion	Ineligible for inclusion	Yes	Ineligible for inclusion
Levofloxacin 500mg tablet/capsule	Yes	Yes	Yes	Yes	Yes	N/A	Yes	Yes	Ineligible for inclusion	Ineligible for inclusion	Yes	Ineligible for inclusion
Levofloxacin 750mg tablet/capsule	Yes	Yes	Yes	Yes	Yes	N/A	Yes	Yes	Ineligible for inclusion	Ineligible for inclusion	Yes	Ineligible for inclusion
Linezolid 600mg tablet	Yes	Yes	Yes	Yes	Yes	N/A	Yes	Yes	Ineligible for inclusion	Ineligible for inclusion	Yes	Ineligible for inclusion
Meropenem 1000mg vial	Yes	Yes	Yes	Yes	Yes	N/A	Yes	Yes	Ineligible for inclusion	Ineligible for inclusion	Yes	Ineligible for inclusion

DR-TB: Drug-Resistant TB

EML: Essential Medicines List

EOI: Expression of Interest

ERP: Expert Review Panel

SRA: Stringent Regulatory Authority

WHO PQ: World Health Organization Prequalification of Medicines Programme

Version: February 2023

Adult Drug-Resistant TB Medicines Dashboard

This Dashboard has been developed by **Stop TB Partnership/Global Drug Facility** in collaboration with **USAID**, the **World Health Organization** and **The Global Fund to fight AIDS, TB & Malaria**.
Stop TB Partnership/Global Drug Facility licensed the TB Medicines Dashboard under a [Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License](https://creativecommons.org/licenses/by-nc-sa/4.0/).

Medicines	WHO Guidelines (DR-TB '20)	WHO Guidelines (DR-TB '22)	EML submitted	EML (2021)	WHO PQ EOI (2021)	WHO PQ Dossier Under Review	WHO PQ listed	Global Fund List of Pharmaceutical Products	Global Fund ERP EOI (Feb 2023)	Global Fund ERP recommended	GDF Catalog	Status
Meropenem 500mg vial	Yes	Yes	Yes	Yes	No	Ineligible for inclusion	Ineligible for inclusion	No	No	Ineligible for inclusion	Ineligible for inclusion	
Meropenem/clavulanate 1000 mg/125 mg vial	Yes	Yes	No	No	Yes	No	No	No	No	Ineligible for inclusion	Ineligible for inclusion	
Moxifloxacin 400mg tablet/capsule	Yes	Yes	Yes	Yes	Yes	N/A	Yes	Yes	Ineligible for inclusion	Ineligible for inclusion	Yes	
PAS 4gm granules	Yes	Yes	Yes	Yes	Yes	No	No	Yes	Ineligible for inclusion	Ineligible for inclusion	No	
PAS Sodium 4gm/5.52gm powder	Yes	Yes	No	No	Yes	N/A	Yes	Yes	Ineligible for inclusion	Ineligible for inclusion	Yes	
Pretomanid 200mg tablet	Yes	Yes	Yes	No	Yes	Yes	Yes	Yes	Yes	Yes	Yes	
Protionamide 250mg tablet/capsule	Yes	Yes	Yes	Yes	Yes	N/A	Yes	Yes	Ineligible for inclusion	Ineligible for inclusion	Yes	

Status
■ Yes
■ No
■ Ineligible for inclusion
■ N/A

DR-TB: Drug-Resistant TB

EML: Essential Medicines List

EOI: Expression of Interest

ERP: Expert Review Panel

SRA: Stringent Regulatory Authority

WHO PQ: World Health Organization Prequalification of Medicines Programme

Version: February 2023

Adult Drug-Resistant TB Medicines Dashboard

This Dashboard has been developed by **Stop TB Partnership/Global Drug Facility** in collaboration with **USAID**, the **World Health Organization** and **The Global Fund to fight AIDS, TB & Malaria**.
Stop TB Partnership/Global Drug Facility licensed the TB Medicines Dashboard under a [Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License](https://creativecommons.org/licenses/by-nc-sa/4.0/).

Medicines	WHO Guidelines (DR-TB '20)	WHO Guidelines (DR-TB '22)	EML submitted	EML (2021)	WHO PQ EOI (2021)	WHO PQ Dossier Under Review	WHO PQ listed	Global Fund List of Pharmaceutical Products	Global Fund ERP EOI (Feb 2023)	Global Fund ERP recommended	GDF Catalog	Status
Pyrazinamide 400mg tablet/capsule	Yes	Yes	Yes	Yes	Yes	N/A	Yes	Yes	Ineligible for inclusion	Ineligible for inclusion	Yes	Yes
Pyrazinamide 500mg tablet/capsule	Yes	Yes	Yes	Yes	Yes	N/A	Yes	Yes	Ineligible for inclusion	Ineligible for inclusion	Yes	Yes
Streptomycin 1000mg vial	Yes	Yes	Yes	Yes	Yes	N/A	Yes	Yes	Ineligible for inclusion	Ineligible for inclusion	Yes	Yes
Terizidone 250mg tablet/capsule	Yes	Yes	Yes	Yes	Yes	N/A	Yes	Yes	Ineligible for inclusion	Ineligible for inclusion	Yes	Yes
Terizidone 500mg tablet	Yes	Yes	No	No	Yes	No	No	No	No	Ineligible for inclusion	Ineligible for inclusion	No

DR-TB: Drug-Resistant TB

EML: Essential Medicines List

EOI: Expression of Interest

ERP: Expert Review Panel

SRA: Stringent Regulatory Authority

WHO PQ: World Health Organization Prequalification of Medicines Programme

Version: February 2023

Adult Drug-Susceptible TB Dashboard

This Dashboard has been developed by **Stop TB Partnership/Global Drug Facility** in collaboration with **USAID**, the **World Health Organization** and **The Global Fund to fight AIDS, TB & Malaria**.
Stop TB Partnership/Global Drug Facility licensed the TB Medicines Dashboard under a [Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License](https://creativecommons.org/licenses/by-nc-sa/4.0/).

Medicines	WHO Guidelines (DS-TB '17)	WHO Guidelines (DS-TB '22)	EML submitted	EML (2021)	WHO PQ EOI (2021)	WHO PQ Dossier Under Review	WHO PQ listed	Global Fund List of Pharmaceutical Products	Global Fund ERP EOI (Feb 2023)	Global Fund ERP recommended	GDF Catalog	Status
												■ Yes ■ No ■ Ineligible for inclusion ■ N/A
Ethambutol 400mg tablet/capsule	Yes	Yes	Yes	Yes	Yes	N/A	Yes	Yes	Ineligible for inclusion	Ineligible for inclusion	Yes	
Ethambutol/Isoniazid/Pyrazinamide/Rifampicin 275/75/400/150mg tablet/capsule	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Ineligible for inclusion	Ineligible for inclusion	Yes	
Ethambutol/Isoniazid/Rifampicin 275/75/150mg tablet/capsule	Yes	Yes	Yes	Yes	Yes	N/A	Yes	Yes	Ineligible for inclusion	Ineligible for inclusion	Yes	
Isoniazid 100mg tablet	Yes	Yes	Yes	Yes	No	Ineligible for inclusion	Yes	Yes	Ineligible for inclusion	Ineligible for inclusion	Yes	
Isoniazid 300mg tablet/capsule	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Ineligible for inclusion	Ineligible for inclusion	Yes	
Isoniazid/Rifampicin 75/150mg tablet/capsule	Yes	Yes	Yes	Yes	Yes	N/A	Yes	Yes	Ineligible for inclusion	Ineligible for inclusion	Yes	
Isoniazid/Rifampicin 150/300mg tablet/capsule	Yes	Yes	Yes	Yes	Yes	N/A	Yes	Yes	Ineligible for inclusion	Ineligible for inclusion	No	

DS-TB: Drug-Susceptible TB

EML: Essential Medicines List

EOI: Expression of Interest

ERP: Expert Review Panel

SRA: Stringent Regulatory Authority

WHO PQ: World Health Organization Prequalification of Medicines Programme

Version: February 2023

Adult Drug-Susceptible TB Dashboard

This Dashboard has been developed by **Stop TB Partnership/Global Drug Facility** in collaboration with **USAID**, the **World Health Organization** and **The Global Fund to fight AIDS, TB & Malaria**.
Stop TB Partnership/Global Drug Facility licensed the TB Medicines Dashboard under a [Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License](https://creativecommons.org/licenses/by-nc-sa/4.0/).

Medicines	WHO Guidelines (DS-TB '17)	WHO Guidelines (DS-TB '22)	EML submitted	EML (2021)	WHO PQ EOI (2021)	WHO PQ Dossier Under Review	WHO PQ listed	Global Fund List of Pharmaceutical Products	Global Fund ERP EOI (Feb 2023)	Global Fund ERP recommended	GDF Catalog	Status
Moxifloxacin 100mg dispersible tablet	Grey	Green	Green	Green	Green	Green	Green	Green	Blue	Blue	Green	Yes
Moxifloxacin 400mg tablet/capsule	Grey	Green	Green	Green	Green	Grey	Green	Green	Blue	Blue	Green	Yes
Pyrazinamide 400mg tablet/capsule	Green	Green	Green	Green	Green	Grey	Green	Green	Blue	Blue	Green	Yes
Pyrazinamide 500mg tablet/capsule	Green	Green	Green	Green	Green	Grey	Green	Green	Blue	Blue	Green	Yes
Rifabutin 150mg capsule	Green	Green	Green	Green	Green	Grey	Green	Green	Green	Red	Green	No
Rifampicin 150mg capsule	Green	Green	Green	Green	Green	Grey	Green	Green	Blue	Blue	Green	Yes
Rifampicin 300mg capsule	Green	Green	Green	Green	Green	Grey	Green	Green	Blue	Blue	Green	Yes

DS-TB: Drug-Susceptible TB

EML: Essential Medicines List

EOI: Expression of Interest

ERP: Expert Review Panel

SRA: Stringent Regulatory Authority

WHO PQ: World Health Organization Prequalification of Medicines Programme

Version: February 2023

Adult Drug-Susceptible TB Dashboard

This Dashboard has been developed by **Stop TB Partnership/Global Drug Facility** in collaboration with **USAID**, the **World Health Organization** and **The Global Fund to fight AIDS, TB & Malaria**.

Stop TB Partnership/Global Drug Facility licensed the TB Medicines Dashboard under a [Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License](https://creativecommons.org/licenses/by-nc-sa/4.0/).

Medicines	WHO Guidelines (DS-TB '17)	WHO Guidelines (DS-TB '22)	EML submitted	EML (2021)	WHO PQ EOI (2021)	WHO PQ Dossier Under Review	WHO PQ listed	Global Fund List of Pharmaceutical Products	Global Fund ERP EOI (Feb 2023)	Global Fund ERP recommended	GDF Catalog	Status
Rifapentine 150mg tablet	Grey	Green	Green	Green	Red	Blue	Green	Green	Red	Blue	Green	Yes
Rifapentine 300mg	Grey	Green	Green	Green	Green	Green	Red	Green	Green	Green	Green	Yes
Rifapentine/Isoniazid 300mg/300mg tablet	Grey	Green	Green	Green	Green	Green	Green	Green	Green	Green	Green	Yes
Rifapentine/Isoniazid/Moxifloxacin 300/75/100mg tablet	Grey	Green	Red	Red	Red	Blue	Blue	Blue	Green	Red	Blue	Ineligible for inclusion
Rifapentine/Isoniazid/Moxifloxacin/Pyrazinamide 300/75/100/375mg tablet	Grey	Green	Red	Red	Red	Blue	Blue	Blue	Green	Red	Blue	Ineligible for inclusion

Status
■ Yes
■ No
■ Ineligible for inclusion
■ N/A

DS-TB: Drug-Susceptible TB

EML: Essential Medicines List

EOI: Expression of Interest

ERP: Expert Review Panel

SRA: Stringent Regulatory Authority

WHO PQ: World Health Organization Prequalification of Medicines Programme

Version: February 2023

Adult TB Preventive Treatment Dashboard

This Dashboard has been developed by **Stop TB Partnership/Global Drug Facility** in collaboration with **USAID**, the **World Health Organization** and **The Global Fund to fight AIDS, TB & Malaria**.
Stop TB Partnership/Global Drug Facility licensed the TB Medicines Dashboard under a [Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License](https://creativecommons.org/licenses/by-nc-sa/4.0/).

Medicines	WHO Guidelines (LTBI '18)	WHO Guidelines (TPT '20)	EML submitted	EML (2021)	WHO PQ EOI (2021)	WHO PQ Dossier Under Review	WHO PQ listed	Global Fund List of Pharmaceutical Products	Global Fund ERP EOI (Feb 2023)	Global Fund ERP recommended	GDF Catalog	Status
Isoniazid 300mg tablet/capsule	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Ineligible for inclusion	Ineligible for inclusion	Yes	Yes
Isoniazid/Rifampicin 75/150mg tablet/capsule	Yes	Yes	Yes	Yes	Yes	N/A	Yes	Yes	Ineligible for inclusion	Ineligible for inclusion	Yes	N/A
Isoniazid/Rifampicin 150/300mg tablet/capsule	Yes	Yes	Yes	Yes	Yes	N/A	Yes	Yes	Ineligible for inclusion	Ineligible for inclusion	No	No
Rifampicin 150mg capsule	Yes	Yes	Yes	Yes	Yes	N/A	Yes	Yes	Ineligible for inclusion	Ineligible for inclusion	Yes	N/A
Rifampicin 300mg capsule	Yes	Yes	Yes	Yes	Yes	N/A	Yes	Yes	Ineligible for inclusion	Ineligible for inclusion	Yes	N/A
Rifapentine 150mg tablet	Yes	Yes	Yes	Yes	No	Ineligible for inclusion	Yes	Yes	No	Ineligible for inclusion	Yes	Ineligible for inclusion
Rifapentine 300mg	Yes	Yes	Yes	Yes	Yes	Yes	No	Yes	Yes	Yes	Yes	No

LTBI: Latent TB Infection
 TPT: TB Preventive Treatment
 EML: Essential Medicines List
 EOI: Expression of Interest
 ERP: Expert Review Panel
 SRA: Stringent Regulatory Authority
 WHO PQ: World Health Organization Prequalification of Medicines Programme
 Version: February 2023

Adult TB Preventive Treatment Dashboard

This Dashboard has been developed by **Stop TB Partnership/Global Drug Facility** in collaboration with **USAID**, the **World Health Organization** and **The Global Fund to fight AIDS, TB & Malaria**.
Stop TB Partnership/Global Drug Facility licensed the TB Medicines Dashboard under a [Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License](#).

Medicines	WHO Guidelines (LTBI '18)	WHO Guidelines (TPT '20)	EML submitted	EML (2021)	WHO PQ EOI (2021)	WHO PQ Dossier Under Review	WHO PQ listed	Global Fund List of Pharmaceutical Products	Global Fund ERP EOI (Feb 2023)	Global Fund ERP recommended	GDF Catalog	Status
Rifapentine/Isoniazid 300mg/300mg tablet	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes
Sulfamethoxazole/Trimethoprim/Isoniazid/Pyridoxine 800/160/300/25mg tablet	Yes	Yes	Yes	Yes	Yes	N/A	Yes	No	Ineligible for inclusion	Ineligible for inclusion	Yes	No

LTBI: Latent TB Infection

TPT: TB Preventive Treatment

EML: Essential Medicines List

EOI: Expression of Interest

ERP: Expert Review Panel

SRA: Stringent Regulatory Authority

WHO PQ: World Health Organization Prequalification of Medicines Programme

Version: February 2023

Pediatric Drug-Resistant TB Medicines Dashboard

This Dashboard has been developed by **Stop TB Partnership/Global Drug Facility** in collaboration with **USAID**, the **World Health Organization** and **The Global Fund to fight AIDS, TB & Malaria**.
Stop TB Partnership/Global Drug Facility licensed the TB Medicines Dashboard under a [Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License](https://creativecommons.org/licenses/by-nc-sa/4.0/).

Medicines	WHO Guidelines (DR-TB '20)	WHO Guidelines (Children & Adolescent '22)	EMLc submitted	EMLc (2021)	WHO PQ EOI (2021)	WHO PQ Dossier Under Review	WHO PQ listed	Global Fund List of Pharmaceutical Products	Global Fund ERP EOI (Feb 2023)	Global Fund ERP recommended	GDF Catalog	Status
Amoxicillin/clavulanate 500mg/125mg tablet	Yes	Yes	Yes	Yes	No	Ineligible for inclusion	Ineligible for inclusion	Yes	Ineligible for inclusion	Ineligible for inclusion	Yes	Yes
Amoxicillin/clavulanic acid 250mg/62.5mg/5mL oral suspension	Yes	Yes	Yes	Yes	No	Ineligible for inclusion	Ineligible for inclusion	Yes	Ineligible for inclusion	Ineligible for inclusion	No	No
Bedaquiline 20mg tablet	Yes	Yes	Yes	Yes	Yes	No	No	Yes	Yes	No	Yes	Yes
Bedaquiline 100mg tablet	Yes	Yes	Yes	Yes	Yes	Yes	No	Yes	Yes	Yes	Yes	Yes
Clofazimine 50mg tablet/capsule	Yes	Yes	Yes	Yes	Yes	N/A	Yes	Yes	Yes	No	Yes	Yes
Cycloserine 125mg capsule	Yes	Yes	Yes	Yes	Yes	N/A	Yes	Yes	Yes	No	Yes	Yes
Delamanid 25mg dispersible tablet	Yes	Yes	Yes	Yes	No	No	No	Yes	Yes	No	Yes	Yes

DR-TB: Drug-Resistant TB

EML: Essential Medicines List

EOI: Expression of Interest

ERP: Expert Review Panel

SRA: Stringent Regulatory Authority

WHO PQ: World Health Organization Prequalification of Medicines Programme

Version: February 2023

Pediatric Drug-Resistant TB Medicines Dashboard

This Dashboard has been developed by **Stop TB Partnership/Global Drug Facility** in collaboration with **USAID**, the **World Health Organization** and **The Global Fund to fight AIDS, TB & Malaria**.
Stop TB Partnership/Global Drug Facility licensed the TB Medicines Dashboard under a [Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License](#).

Medicines	WHO Guidelines (DR-TB '20)	WHO Guidelines (Children & Adolescent '22)	EMLc submitted	EMLc (2021)	WHO PQ EOI (2021)	WHO PQ Dossier Under Review	WHO PQ listed	Global Fund List of Pharmaceutical Products	Global Fund ERP EOI (Feb 2023)	Global Fund ERP recommended	GDF Catalog	Status
Delamanid 50mg dispersible tablet	Yes	Yes	No	No	Yes	No	No	No	No	Ineligible for inclusion	Ineligible for inclusion	Ineligible for inclusion
Delamanid 50mg tablet	Yes	Yes	Yes	Yes	Yes	N/A	Yes	Yes	Ineligible for inclusion	Ineligible for inclusion	Yes	Yes
Ethambutol 25mg/mL oral liquid	Yes	Yes	Yes	Yes	No	Ineligible for inclusion	Ineligible for inclusion	No	No	Ineligible for inclusion	Ineligible for inclusion	Ineligible for inclusion
Ethambutol 50mg dispersible tablet	Yes	Yes	No	No	No	N/A	Yes	No	No	Ineligible for inclusion	Ineligible for inclusion	Ineligible for inclusion
Ethambutol 100mg dispersible tablet	Yes	Yes	Yes	Yes	Yes	N/A	Yes	Yes	Ineligible for inclusion	Ineligible for inclusion	Yes	Yes
Ethambutol 100mg tablet	Yes	Yes	Yes	Yes	No	Ineligible for inclusion	Yes	Yes	No	Ineligible for inclusion	Yes	Yes
Ethionamide 125mg dispersible tablet	Yes	Yes	Yes	Yes	Yes	N/A	Yes	Yes	Ineligible for inclusion	Ineligible for inclusion	Yes	Yes

DR-TB: Drug-Resistant TB
 EML: Essential Medicines List
 EOI: Expression of Interest
 ERP: Expert Review Panel
 SRA: Stringent Regulatory Authority
 WHO PQ: World Health Organization Prequalification of Medicines Programme
 Version: February 2023

Pediatric Drug-Resistant TB Medicines Dashboard

This Dashboard has been developed by **Stop TB Partnership/Global Drug Facility** in collaboration with **USAID**, the **World Health Organization** and **The Global Fund to fight AIDS, TB & Malaria**.
Stop TB Partnership/Global Drug Facility licensed the TB Medicines Dashboard under a [Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License](https://creativecommons.org/licenses/by-nc-sa/4.0/).

Medicines	WHO Guidelines (DR-TB '20)	WHO Guidelines (Children & Adolescent '22)	EMLc submitted	EMLc (2021)	WHO PQ EOI (2021)	WHO PQ Dossier Under Review	WHO PQ listed	Global Fund List of Pharmaceutical Products	Global Fund ERP EOI (Feb 2023)	Global Fund ERP recommended	GDF Catalog	Status
Ethionamide 125mg tablet/capsule	Yes	Yes	Yes	Yes	No	Ineligible for inclusion	Yes	Yes	No	Ineligible for inclusion	No	No
Isoniazid 50mg dispersible tablet	Yes	Yes	No	No	No	Ineligible for inclusion	Yes	Yes	No	Ineligible for inclusion	No	No
Isoniazid 50mg/5mL oral liquid	Yes	Yes	Yes	Yes	No	Ineligible for inclusion	Ineligible for inclusion	No	No	Ineligible for inclusion	Ineligible for inclusion	Ineligible for inclusion
Isoniazid 100mg dispersible tablet	Yes	Yes	Yes	Yes	Yes	N/A	Yes	Yes	Ineligible for inclusion	Ineligible for inclusion	Yes	Ineligible for inclusion
Isoniazid 100mg tablet	Yes	Yes	Yes	Yes	No	Ineligible for inclusion	Yes	Yes	Ineligible for inclusion	Ineligible for inclusion	Yes	Yes
Isoniazid 300mg tablet/capsule	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Ineligible for inclusion	Ineligible for inclusion	Yes	Yes
Levofloxacin 100mg dispersible tablet	Yes	Yes	Yes	Yes	Yes	N/A	Yes	Yes	Ineligible for inclusion	Ineligible for inclusion	Yes	Yes

Status
● Yes
● No
● Ineligible for inclusion
● N/A

DR-TB: Drug-Resistant TB
 EML: Essential Medicines List
 EOI: Expression of Interest
 ERP: Expert Review Panel
 SRA: Stringent Regulatory Authority
 WHO PQ: World Health Organization Prequalification of Medicines Programme
 Version: February 2023

Pediatric Drug-Resistant TB Medicines Dashboard

This Dashboard has been developed by **Stop TB Partnership/Global Drug Facility** in collaboration with **USAID**, the **World Health Organization** and **The Global Fund to fight AIDS, TB & Malaria**.
Stop TB Partnership/Global Drug Facility licensed the TB Medicines Dashboard under a [Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License](#).

Medicines	WHO Guidelines (DR-TB '20)	WHO Guidelines (Children & Adolescent '22)	EMLc submitted	EMLc (2021)	WHO PQ EOI (2021)	WHO PQ Dossier Under Review	WHO PQ listed	Global Fund List of Pharmaceutical Products	Global Fund ERP EOI (Feb 2023)	Global Fund ERP recommended	GDF Catalog	Status
Linezolid 20mg/mL oral suspension	Yes	Yes	Yes	Yes	Yes	No	No	No	No	Ineligible for inclusion	No	No
Linezolid 150mg dispersible tablet	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes
Linezolid 600mg tablet	Yes	Yes	Yes	Yes	Yes	N/A	Yes	Yes	Ineligible for inclusion	Ineligible for inclusion	Yes	Ineligible for inclusion
Meropenem 500mg vial	Yes	Yes	Yes	Yes	No	Ineligible for inclusion	Ineligible for inclusion	No	No	Ineligible for inclusion	Ineligible for inclusion	Ineligible for inclusion
Meropenem 1000mg vial	Yes	Yes	Yes	Yes	Yes	N/A	Yes	Yes	Ineligible for inclusion	Ineligible for inclusion	Yes	Ineligible for inclusion
Meropenem/clavulanate 1000 mg/125 mg vial	Yes	Yes	No	No	Yes	No	No	No	No	Ineligible for inclusion	Ineligible for inclusion	No
Moxifloxacin 100mg dispersible tablet	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Ineligible for inclusion	Ineligible for inclusion	Yes	Yes

DR-TB: Drug-Resistant TB
 EML: Essential Medicines List
 EOI: Expression of Interest
 ERP: Expert Review Panel
 SRA: Stringent Regulatory Authority
 WHO PQ: World Health Organization Prequalification of Medicines Programme
 Version: February 2023

Pediatric Drug-Resistant TB Medicines Dashboard

This Dashboard has been developed by **Stop TB Partnership/Global Drug Facility** in collaboration with **USAID**, the **World Health Organization** and **The Global Fund to fight AIDS, TB & Malaria**.

Stop TB Partnership/Global Drug Facility licensed the TB Medicines Dashboard under a [Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License](https://creativecommons.org/licenses/by-nc-sa/4.0/).

Medicines	WHO Guidelines (DR-TB '20)	WHO Guidelines (Children & Adolescent '22)	EMLc submitted	EMLc (2021)	WHO PQ EOI (2021)	WHO PQ Dossier Under Review	WHO PQ listed	Global Fund List of Pharmaceutical Products	Global Fund ERP EOI (Feb 2023)	Global Fund ERP recommended	GDF Catalog	Status
Moxifloxacin 400mg tablet/capsule	Yes	Yes	Yes	Yes	Yes	N/A	Yes	Yes	Ineligible for inclusion	Ineligible for inclusion	Yes	Yes
PAS 4gm granules	Yes	Yes	Yes	Yes	Yes	No	No	Yes	Ineligible for inclusion	Ineligible for inclusion	No	No
PAS Sodium 4gm/5.52gm powder	Yes	Yes	No	No	Yes	N/A	Yes	Yes	Ineligible for inclusion	Ineligible for inclusion	Yes	Yes
Pyrazinamide 30mg/mL oral liquid	Yes	Yes	Yes	Yes	No	Ineligible for inclusion	Ineligible for inclusion	No	No	Ineligible for inclusion	Ineligible for inclusion	Ineligible for inclusion
Pyrazinamide 150mg dispersible tablet	Yes	Yes	Yes	Yes	Yes	N/A	Yes	Yes	Ineligible for inclusion	Ineligible for inclusion	Yes	Yes

DR-TB: Drug-Resistant TB

EML: Essential Medicines List

EOI: Expression of Interest

ERP: Expert Review Panel

SRA: Stringent Regulatory Authority

WHO PQ: World Health Organization Prequalification of Medicines Programme

Version: February 2023

Pediatric Drug-Susceptible TB Medicines Dashboard

This Dashboard has been developed by **Stop TB Partnership/Global Drug Facility** in collaboration with **USAID**, the **World Health Organization** and **The Global Fund to fight AIDS, TB & Malaria**.
Stop TB Partnership/Global Drug Facility licensed the TB Medicines Dashboard under a [Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License](https://creativecommons.org/licenses/by-nc-sa/4.0/).

Medicines	WHO Guidelines (DS-TB '17)	WHO Guidelines (Children & Adolescent '22)	EMLc submitted	EMLc (2021)	WHO PQ EOI (2021)	WHO PQ Dossier Under Review	WHO PQ listed	Global Fund List of Pharmaceutical Products	Global Fund ERP EOI (Feb 2023)	Global Fund ERP recommended	GDF Catalog	Status
Ethambutol 25mg/mL oral liquid	Yes	Yes	Yes	Yes	No	Ineligible for inclusion	Ineligible for inclusion	No	No	Ineligible for inclusion	Ineligible for inclusion	
Ethambutol 50mg dispersible tablet	Yes	Yes	No	No	No	N/A	Yes	No	No	Ineligible for inclusion	Ineligible for inclusion	
Ethambutol 100mg dispersible tablet	Yes	Yes	Yes	Yes	Yes	N/A	Yes	Yes	Ineligible for inclusion	Ineligible for inclusion	Yes	
Ethambutol 100mg tablet	Yes	Yes	Yes	Yes	No	Ineligible for inclusion	Yes	Yes	No	Ineligible for inclusion	Yes	
Ethionamide 125mg dispersible tablet	N/A	Yes	Yes	Yes	Yes	N/A	Yes	Yes	Ineligible for inclusion	Ineligible for inclusion	Yes	
Isoniazid 50mg dispersible tablet	Yes	Yes	No	No	No	Ineligible for inclusion	Yes	Yes	No	Ineligible for inclusion	No	
Isoniazid 50mg/5mL oral liquid	Yes	Yes	Yes	Yes	No	Ineligible for inclusion	Ineligible for inclusion	No	No	Ineligible for inclusion	Ineligible for inclusion	

DS-TB: Drug-Susceptible TB

EML: Essential Medicines List

EOI: Expression of Interest

ERP: Expert Review Panel

SRA: Stringent Regulatory Authority

WHO PQ: World Health Organization Prequalification of Medicines Programme

Version: February 2023

Pediatric Drug-Susceptible TB Medicines Dashboard

This Dashboard has been developed by **Stop TB Partnership/Global Drug Facility** in collaboration with **USAID**, the **World Health Organization** and **The Global Fund to fight AIDS, TB & Malaria**.
Stop TB Partnership/Global Drug Facility licensed the TB Medicines Dashboard under a [Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License](https://creativecommons.org/licenses/by-nc-sa/4.0/).

Medicines	WHO Guidelines (DS-TB '17)	WHO Guidelines (Children & Adolescent '22)	EMLc submitted	EMLc (2021)	WHO PQ EOI (2021)	WHO PQ Dossier Under Review	WHO PQ listed	Global Fund List of Pharmaceutical Products	Global Fund ERP EOI (Feb 2023)	Global Fund ERP recommended	GDF Catalog	Status
												<ul style="list-style-type: none"> ■ Yes ■ No ■ Ineligible for inclusion ■ N/A
Isoniazid 100mg dispersible tablet	Yes	Yes	Yes	Yes	Yes	N/A	Yes	Yes	Ineligible for inclusion	Ineligible for inclusion	Yes	
Isoniazid 100mg tablet	Yes	Yes	Yes	Yes	No	Ineligible for inclusion	Yes	Yes	Ineligible for inclusion	Ineligible for inclusion	Yes	
Isoniazid 300mg tablet/capsule	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Ineligible for inclusion	Ineligible for inclusion	Yes	
Pyrazinamide 30mg/mL oral liquid	Yes	Yes	Yes	Yes	No	Ineligible for inclusion	Ineligible for inclusion	No	No	Ineligible for inclusion	Ineligible for inclusion	
Pyrazinamide 150mg dispersible tablet	Yes	Yes	Yes	Yes	Yes	N/A	Yes	Yes	Ineligible for inclusion	Ineligible for inclusion	Yes	
Rifampicin 20mg/mL oral liquid	Yes	Yes	Yes	Yes	No	Ineligible for inclusion	Ineligible for inclusion	No	No	Ineligible for inclusion	No	
Rifampicin/Isoniazid 75/50 dispersible tablet	Yes	Yes	Yes	Yes	Yes	N/A	Yes	Yes	Ineligible for inclusion	Ineligible for inclusion	Yes	

DS-TB: Drug-Susceptible TB
 EML: Essential Medicines List
 EOI: Expression of Interest
 ERP: Expert Review Panel
 SRA: Stringent Regulatory Authority
 WHO PQ: World Health Organization Prequalification of Medicines Programme
 Version: February 2023

Pediatric Drug-Susceptible TB Medicines Dashboard

This Dashboard has been developed by **Stop TB Partnership/Global Drug Facility** in collaboration with **USAID**, the **World Health Organization** and **The Global Fund to fight AIDS, TB & Malaria**.
Stop TB Partnership/Global Drug Facility licensed the TB Medicines Dashboard under a [Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License](#).

Medicines	WHO Guidelines (DS-TB '17)	WHO Guidelines (Children & Adolescent '22)	EMLc submitted	EMLc (2021)	WHO PQ EOI (2021)	WHO PQ Dossier Under Review	WHO PQ listed	Global Fund List of Pharmaceutical Products	Global Fund ERP EOI (Feb 2023)	Global Fund ERP recommended	GDF Catalog	Status
Rifampicin/Isoniazid/Pyrazinamide 75/50/150mg dispersible tablet												Yes

DS-TB: Drug-Susceptible TB

EML: Essential Medicines List

EOI: Expression of Interest

ERP: Expert Review Panel

SRA: Stringent Regulatory Authority

WHO PQ: World Health Organization Prequalification of Medicines Programme

Version: February 2023

Pediatric TB Preventive Treatment Medicines Dashboard

This Dashboard has been developed by **Stop TB Partnership/Global Drug Facility** in collaboration with **USAID**, the **World Health Organization** and **The Global Fund to fight AIDS, TB & Malaria**.

Stop TB Partnership/Global Drug Facility licensed the TB Medicines Dashboard under a [Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License](https://creativecommons.org/licenses/by-nc-sa/4.0/).

Medicines	WHO Guidelines (TPT '20)	WHO Guidelines (Children & Adolescent '22)	EMLc submitted	EMLc (2021)	WHO PQ EOI (2021)	WHO PQ Dossier Under Review	WHO PQ listed	Global Fund List of Pharmaceutical Products	Global Fund ERP EOI (Feb 2023)	Global Fund ERP recommended	GDF Catalog	Status
Isoniazid 50mg dispersible tablet	Yes	Yes	No	No	No	Ineligible for inclusion	Yes	Yes	No	Ineligible for inclusion	No	No
Isoniazid 50mg/5mL oral liquid	Yes	Yes	Yes	Yes	No	Ineligible for inclusion	Ineligible for inclusion	No	No	Ineligible for inclusion	Ineligible for inclusion	No
Isoniazid 100mg dispersible tablet	Yes	Yes	Yes	Yes	Yes	N/A	Yes	Yes	Ineligible for inclusion	Ineligible for inclusion	Yes	Ineligible for inclusion
Isoniazid 100mg tablet	Yes	Yes	Yes	Yes	No	Ineligible for inclusion	Yes	Yes	Ineligible for inclusion	Ineligible for inclusion	Yes	Ineligible for inclusion
Isoniazid 300mg tablet/capsule	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Ineligible for inclusion	Ineligible for inclusion	Yes	Yes
Levofloxacin 100mg dispersible tablet	Yes	Yes	Yes	Yes	Yes	N/A	Yes	Yes	Ineligible for inclusion	Ineligible for inclusion	Yes	Ineligible for inclusion
Rifampicin 20mg/mL oral liquid	Yes	Yes	Yes	Yes	No	Ineligible for inclusion	Ineligible for inclusion	No	No	Ineligible for inclusion	No	No
Rifampicin/Isoniazid 75/50 dispersible tablet	Yes	Yes	Yes	Yes	Yes	N/A	Yes	Yes	Ineligible for inclusion	Ineligible for inclusion	Yes	Yes

Status
● Yes
● No
● Ineligible for inclusion
● N/A

LTBI: Latent TB Infection

EML: Essential Medicines List

EOI: Expression of Interest

ERP: Expert Review Panel

SRA: Stringent Regulatory Authority

WHO PQ: World Health Organization Prequalification of Medicines Programme

Version: February 2023

Pediatric TB Preventive Treatment Medicines Dashboard

This Dashboard has been developed by **Stop TB Partnership/Global Drug Facility** in collaboration with **USAID**, the **World Health Organization** and **The Global Fund to fight AIDS, TB & Malaria**.

Stop TB Partnership/Global Drug Facility licensed the TB Medicines Dashboard under a [Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License](https://creativecommons.org/licenses/by-nc-sa/4.0/).

Medicines	WHO Guidelines (TPT '20)	WHO Guidelines (Children & Adolescent '22)	EMLc submitted	EMLc (2021)	WHO PQ EOI (2021)	WHO PQ Dossier Under Review	WHO PQ listed	Global Fund List of Pharmaceutical Products	Global Fund ERP EOI (Feb 2023)	Global Fund ERP recommended	GDF Catalog	Status
Rifapentine 150mg dispersible tablet	Yes	Yes	No	No	Yes	No	No	No	Yes	No	Ineligible for inclusion	No
Rifapentine 150mg tablet	Yes	Yes	Yes	Yes	No	Ineligible for inclusion	Yes	Yes	No	Ineligible for inclusion	Yes	No
Rifapentine 300mg	Yes	Yes	Yes	Yes	Yes	Yes	No	Yes	Yes	Yes	Yes	No
Rifapentine/Isoniazid 300mg/300mg tablet	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes
Sulfamethoxazole/Trimethoprim/Isoniazid/Pyridoxine 400/80/150/12.5mg tablet	Yes	Yes	N/A	No	Yes	No	No	No	Ineligible for inclusion	Ineligible for inclusion	Ineligible for inclusion	Ineligible for inclusion

Status
■ Yes
■ No
■ Ineligible for inclusion
■ N/A

LTBI: Latent TB Infection

EML: Essential Medicines List

EOI: Expression of Interest

ERP: Expert Review Panel

SRA: Stringent Regulatory Authority

WHO PQ: World Health Organization Prequalification of Medicines Programme

Version: February 2023

Formulations no longer recommended TB Medicines Dashboard

This Dashboard has been developed by **Stop TB Partnership/Global Drug Facility** in collaboration with **USAID**, the **World Health Organization** and **The Global Fund to fight AIDS, TB & Malaria**.
Stop TB Partnership/Global Drug Facility licensed the TB Medicines Dashboard under a [Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License](https://creativecommons.org/licenses/by-nc-sa/4.0/).

Medicines	EML	EMLC	WHO PQ EOI	WHO PQ listed	Global Fund List of Pharmaceutical Products	Global Fund ERP recommended	GDF Catalog
Amikacin 1000mg vial	Removed	Removed	No	Ineligible for inclusion	No	Ineligible for inclusion	Ineligible for inclusion
Amoxicillin/clavulanate 875mg/125mg tablet	No	No	No	Ineligible for inclusion	Yes	Ineligible for inclusion	Removed
Amoxicillin/clavulanic acid 125mg/31.25mg/5mL oral suspension	Removed	Removed	No	Ineligible for inclusion	Yes	Ineligible for inclusion	No
Bedaquiline 100mg dispersable tablet	No	No	Removed	Ineligible for inclusion	Ineligible for inclusion	Ineligible for inclusion	Ineligible for inclusion
Capreomycin 500mg vial	No	No	Removed	Removed	Removed	Ineligible for inclusion	Removed
Capreomycin 750mg vial	No	No	No	Ineligible for inclusion	Ineligible for inclusion	Ineligible for inclusion	Ineligible for inclusion
Capreomycin 1000mg vial	Removed	Removed	Removed	Yes	Removed	Ineligible for inclusion	Removed
Ethambutol 200mg tablet/capsule	No	No	Removed	Ineligible for inclusion	Ineligible for inclusion	Ineligible for inclusion	Ineligible for inclusion

Status

- Yes
- No
- Ineligible for inclusion
- Removed
- Rejected
- N/A

EML: Essential Medicines List

EOI: Expression of Interest

ERP: Expert Review Panel

SRA: Stringent Regulatory Authority

WHO PQ: World Health Organization Prequalification of Medicines Programme

Version: February 2023

Formulations no longer recommended TB Medicines Dashboard

This Dashboard has been developed by **Stop TB Partnership/Global Drug Facility** in collaboration with **USAID**, the **World Health Organization** and **The Global Fund to fight AIDS, TB & Malaria**.
Stop TB Partnership/Global Drug Facility licensed the TB Medicines Dashboard under a [Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License](https://creativecommons.org/licenses/by-nc-sa/4.0/).

Medicines	EML	EMLC	WHO PQ EOI	WHO PQ listed	Global Fund List of Pharmaceutical Products	Global Fund ERP recommended	GDF Catalog
Ethambutol 275mg tablet/capsule	No	No	Removed	Ineligible for inclusion	Ineligible for inclusion	Ineligible for inclusion	Ineligible for inclusion
Ethambutol 1000mg vial	Rejected	Rejected	No	Ineligible for inclusion	Ineligible for inclusion	Ineligible for inclusion	Ineligible for inclusion
Ethambutol 2000mg vial	Rejected	Rejected	No	Ineligible for inclusion	Ineligible for inclusion	Ineligible for inclusion	Ineligible for inclusion
Ethambutol/Isoniazid 400/150mg tablet/capsule	Removed	Removed	Removed	Yes	Removed	Ineligible for inclusion	Removed
Isoniazid 50mg tablet scored	Removed	Removed	No	Ineligible for inclusion	Yes	Ineligible for inclusion	Ineligible for inclusion
Isoniazid 100mg/5mL oral liquid	Rejected	Rejected	No	Ineligible for inclusion	Ineligible for inclusion	Ineligible for inclusion	Ineligible for inclusion
Isoniazid 100mg/mL vial	Rejected	Rejected	No	Ineligible for inclusion	Ineligible for inclusion	Ineligible for inclusion	Ineligible for inclusion
Isoniazid/Pyrazinamide/Rifampicin 75/400/150mg tablet/capsule	Removed	N/A	No	Ineligible for inclusion	No	Ineligible for inclusion	Ineligible for inclusion

Status

- Yes
- No
- Ineligible for inclusion
- Removed
- Rejected
- N/A

EML: Essential Medicines List

EOI: Expression of Interest

ERP: Expert Review Panel

SRA: Stringent Regulatory Authority

WHO PQ: World Health Organization Prequalification of Medicines Programme

Version: February 2023

Formulations no longer recommended TB Medicines Dashboard

This Dashboard has been developed by **Stop TB Partnership/Global Drug Facility** in collaboration with **USAID**, the **World Health Organization** and **The Global Fund to fight AIDS, TB & Malaria**.
Stop TB Partnership/Global Drug Facility licensed the TB Medicines Dashboard under a [Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License](https://creativecommons.org/licenses/by-nc-sa/4.0/).

Medicines	EML	EMLC	WHO PQ EOI	WHO PQ listed	Global Fund List of Pharmaceutical Products	Global Fund ERP recommended	GDF Catalog
Isoniazid/Pyrazinamide/Rifampicin 150/500/150mg tablet/capsule	Removed	No	Removed	Ineligible for inclusion	Ineligible for inclusion	Ineligible for inclusion	Ineligible for inclusion
Isoniazid/Rifampicin 150/150mg tablet/capsule	Removed	No	Removed	Yes	Removed	Ineligible for inclusion	Removed
Kanamycin 500mg vial	No	No	Removed	Yes	Removed	Ineligible for inclusion	Removed
Kanamycin 1000mg vial	Removed	Removed	Removed	Yes	Removed	Ineligible for inclusion	Removed
Linezolid 400mg tablet	Removed	Removed	No	Ineligible for inclusion	No	Ineligible for inclusion	Ineligible for inclusion
Linezolid injection 2mg/mL in 300mL bag	Removed	Removed	No	Ineligible for inclusion	Yes	Ineligible for inclusion	No
PAS 500mg tablet	Removed	Removed	No	Ineligible for inclusion	No	Ineligible for inclusion	Ineligible for inclusion
PAS Injection	Rejected	Rejected	No	Ineligible for inclusion	Ineligible for inclusion	Ineligible for inclusion	Ineligible for inclusion

Status

- Yes
- No
- Ineligible for inclusion
- Removed
- Rejected
- N/A

EML: Essential Medicines List

EOI: Expression of Interest

ERP: Expert Review Panel

SRA: Stringent Regulatory Authority

WHO PQ: World Health Organization Prequalification of Medicines Programme

Version: February 2023

Formulations no longer recommended TB Medicines Dashboard

This Dashboard has been developed by **Stop TB Partnership/Global Drug Facility** in collaboration with **USAID**, the **World Health Organization** and **The Global Fund to fight AIDS, TB & Malaria**.
Stop TB Partnership/Global Drug Facility licensed the TB Medicines Dashboard under a [Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License](https://creativecommons.org/licenses/by-nc-sa/4.0/).

Medicines	EML	EMLC	WHO PQ EOI	WHO PQ listed	Global Fund List of Pharmaceutical Products	Global Fund ERP recommended	GDF Catalog
PAS Sodium 4gm/9.2gm powder	No	No	No	No	Yes	Ineligible for inclusion	No
PAS Sodium 100gm powder	No	No	No	No	Yes	Ineligible for inclusion	No
Pyrazinamide 150mg tablet scored	Removed	Removed	No	Ineligible for inclusion	No	Ineligible for inclusion	Ineligible for inclusion
Pyrazinamide 250mg tablet/capsule	No	No	Removed	Ineligible for inclusion	Ineligible for inclusion	Ineligible for inclusion	Ineligible for inclusion
Rifampicin 450mg tablet	No	No	No	Ineligible for inclusion	Yes	Ineligible for inclusion	No
Rifampicin 600mg vial	Rejected	Rejected	No	Ineligible for inclusion	Ineligible for inclusion	Ineligible for inclusion	Ineligible for inclusion
Rifapentine 300mg scored, dispersible	No	No	Removed	Ineligible for inclusion	Ineligible for inclusion	Ineligible for inclusion	Ineligible for inclusion
Rifapentine/Isoniazid 150mg/150mg dispersible tablet	No	No	Removed	Ineligible for inclusion	Ineligible for inclusion	Ineligible for inclusion	Ineligible for inclusion

Status

- Yes
- No
- Ineligible for inclusion
- Removed
- Rejected
- N/A

EML: Essential Medicines List

EOI: Expression of Interest

ERP: Expert Review Panel






















SRA: Stringent Regulatory Authority

WHO PQ: World Health Organization Prequalification of Medicines Programme







Version: February 2023

Formulations no longer recommended TB Medicines Dashboard

This Dashboard has been developed by **Stop TB Partnership/Global Drug Facility** in collaboration with **USAID**, the **World Health Organization** and **The Global Fund to fight AIDS, TB & Malaria**.
Stop TB Partnership/Global Drug Facility licensed the TB Medicines Dashboard under a [Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License](https://creativecommons.org/licenses/by-nc-sa/4.0/).

	EML	EMLC	WHO PQ EOI	WHO PQ listed	Global Fund List of Pharmaceutical Products	Global Fund ERP recommended	GDF Catalog
Medicines							
Rifapentine/Isoniazid 300mg/300mg dispersible tablet							
Streptomycin 750mg vial							
Terizidone 300mg tablet/capsule							

Status

-  Yes
-  No
-  Ineligible for inclusion
-  Removed
-  Rejected
-  N/A

EML: Essential Medicines List

EOI: Expression of Interest

ERP: Expert Review Panel

SRA: Stringent Regulatory Authority

WHO PQ: World Health Organization Prequalification of Medicines Programme

Version: February 2023